• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新诊断帕金森病中与认知功能减退相关的多重用药:一项横断面研究

Polypharmacy Associated with Cognitive Decline in Newly Diagnosed Parkinson's Disease: A Cross-Sectional Study.

作者信息

Ishii Nobuyuki, Mochizuki Hitoshi, Sakai Katsuya, Ogawa Go, Shiomi Kazutaka, Nakazato Masamitsu

机构信息

Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan.

出版信息

Dement Geriatr Cogn Dis Extra. 2019 Sep 10;9(3):338-343. doi: 10.1159/000502351. eCollection 2019 Sep-Dec.

DOI:10.1159/000502351
PMID:31608098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6787424/
Abstract

AIMS

Polypharmacy is well known to affect cognitive function in community-dwelling older adults. However, the effect of polypharmacy on cognitive function in patients with newly diagnosed Parkinson's disease remains unknown. Here, we evaluated the association between polypharmacy and cognitive function in patients with newly diagnosed Parkinson's disease.

METHODS

This cross-sectional study enrolled 131 consecutive hospitalized patients with newly diagnosed Parkinson's disease. Cognitive function was evaluated with the Mini-Mental State Examination and analyzed between groups of patients with or without polypharmacy. Comparisons were adjusted for confounders by performing inverse probability weighting with propensity scores.

RESULTS

After inverse probability weighting, patients in the polypharmacy group had a significantly lower Mini-Mental State Examination score than patients in the nonpolypharmacy group (26.2 vs. 27.7, = 0.001).

CONCLUSION

Polypharmacy was associated with cognitive decline in patients with newly diagnosed Parkinson's disease. This finding suggests that medication reduction might serve as a promising intervention to prevent the development of dementia in patients with early Parkinson's disease. Further prospective studies are needed to determine whether medication reduction improves cognitive function in patients with newly diagnosed Parkinson's disease.

摘要

目的

众所周知,多重用药会影响社区居住的老年人的认知功能。然而,多重用药对新诊断帕金森病患者认知功能的影响尚不清楚。在此,我们评估了新诊断帕金森病患者多重用药与认知功能之间的关联。

方法

这项横断面研究纳入了131例连续住院的新诊断帕金森病患者。使用简易精神状态检查表评估认知功能,并在有或没有多重用药的患者组之间进行分析。通过倾向评分进行逆概率加权来调整混杂因素。

结果

经过逆概率加权后,多重用药组患者的简易精神状态检查表得分显著低于非多重用药组患者(26.2对27.7,P = 0.001)。

结论

多重用药与新诊断帕金森病患者的认知衰退有关。这一发现表明,减少用药可能是预防早期帕金森病患者痴呆症发展的一种有前景的干预措施。需要进一步的前瞻性研究来确定减少用药是否能改善新诊断帕金森病患者的认知功能。

相似文献

1
Polypharmacy Associated with Cognitive Decline in Newly Diagnosed Parkinson's Disease: A Cross-Sectional Study.新诊断帕金森病中与认知功能减退相关的多重用药:一项横断面研究
Dement Geriatr Cogn Dis Extra. 2019 Sep 10;9(3):338-343. doi: 10.1159/000502351. eCollection 2019 Sep-Dec.
2
Anticholinergic Burden, Polypharmacy, and Cognition in Parkinson's Disease Patients with Mild Cognitive Impairment: A Cross-Sectional Observational Study.抗胆碱能负担、多种药物治疗与轻度认知障碍的帕金森病患者认知功能:一项横断面观察性研究。
Dement Geriatr Cogn Disord. 2022;51(5):386-395. doi: 10.1159/000526863. Epub 2022 Oct 21.
3
Cognitive profiles and optimal cut-offs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition.认知特征及常规认知测试在老年帕金森病、帕金森病痴呆、阿尔茨海默病及认知正常个体中的最佳截断值。
Psychogeriatrics. 2020 Jan;20(1):20-27. doi: 10.1111/psyg.12451. Epub 2019 Mar 25.
4
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.用于路易体痴呆、帕金森病痴呆及帕金森病认知障碍的胆碱酯酶抑制剂
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD006504. doi: 10.1002/14651858.CD006504.pub2.
5
The relationship between polypharmacy and trajectories of cognitive decline in people with dementia: A large representative cohort study.痴呆患者药物滥用与认知能力下降轨迹的关系:一项大型代表性队列研究。
Exp Gerontol. 2019 Jun;120:62-67. doi: 10.1016/j.exger.2019.02.019. Epub 2019 Mar 1.
6
Mild Behavioral Impairment in Parkinson's Disease: Data from the Parkinson's Disease Cognitive Impairment Study (PACOS).帕金森病的轻度行为障碍:帕金森病认知障碍研究(PACOS)的数据。
J Alzheimers Dis. 2019;68(4):1603-1610. doi: 10.3233/JAD-181117.
7
Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.蒙特利尔认知评估量表、简易精神状态检查和 SCOPA-Cog 在非痴呆帕金森病患者中的变化反应性。
Dement Geriatr Cogn Disord. 2019;47(4-6):187-197. doi: 10.1159/000496454. Epub 2019 Jul 17.
8
Co-morbidity and polypharmacy in Parkinson's disease: insights from a large Scottish primary care database.帕金森病的共病与多重用药:来自苏格兰大型初级保健数据库的见解
BMC Neurol. 2017 Jul 1;17(1):126. doi: 10.1186/s12883-017-0904-4.
9
Predicting early cognitive decline in newly-diagnosed Parkinson's patients: A practical model.预测新诊断帕金森病患者的早期认知衰退:实用模型。
Parkinsonism Relat Disord. 2018 Nov;56:70-75. doi: 10.1016/j.parkreldis.2018.06.031. Epub 2018 Jun 19.
10
Mild cognitive impairment in Parkinson's disease: the Parkinson's disease cognitive study (PACOS).帕金森病轻度认知障碍:帕金森病认知研究(PACOS)。
J Neurol. 2018 May;265(5):1050-1058. doi: 10.1007/s00415-018-8800-4. Epub 2018 Feb 24.

引用本文的文献

1
Polypharmacy and its association with dementia, Parkinson's disease, and mortality risk in UK adults: a multistate modeling approach.多重用药及其与英国成年人痴呆症、帕金森病和死亡风险的关联:一种多状态建模方法。
Geroscience. 2025 Mar 13. doi: 10.1007/s11357-025-01586-w.
2
A Review of Risk Factors for Polypharmacy: Age, Level of Education, and Physician's Attitude.多重用药风险因素综述:年龄、教育程度及医生态度
Cureus. 2024 Oct 19;16(10):e71868. doi: 10.7759/cureus.71868. eCollection 2024 Oct.
3
Prevalence and prescribers' knowledge of psychotropic polypharmacy in the Bono, Bono East, and Ahafo Regions, Ghana.加纳博诺、博诺东部和阿哈福地区精神药物多药联用的患病率及开方者的知晓情况
Heliyon. 2024 Jan 8;10(2):e24243. doi: 10.1016/j.heliyon.2024.e24243. eCollection 2024 Jan 30.
4
The Impact of Polypharmacy on Management of Lower Urinary Tract Symptoms in Parkinson's Disease.多药治疗对帕金森病下尿路症状管理的影响。
Drugs Aging. 2023 Oct;40(10):909-917. doi: 10.1007/s40266-023-01060-2. Epub 2023 Aug 31.
5
A Systematic Review of the Current Evidence from Randomised Controlled Trials on the Impact of Medication Optimisation or Pharmacological Interventions on Quantitative Measures of Cognitive Function in Geriatric Patients.一项对随机对照试验中关于药物优化或药物干预对老年患者认知功能定量测量影响的现有证据的系统评价。
Drugs Aging. 2022 Nov;39(11):863-874. doi: 10.1007/s40266-022-00980-9. Epub 2022 Oct 26.
6
Similarities, differences and overlaps between frailty and Parkinson's disease.衰弱与帕金森病之间的异同与重叠
Geriatr Gerontol Int. 2022 Apr;22(4):259-270. doi: 10.1111/ggi.14362. Epub 2022 Mar 3.
7
Polypharmacy and Hyperpolypharmacy in Older Individuals with Parkinson's Disease: A Systematic Review and Meta-Analysis.帕金森病老年患者的多药治疗和超多药治疗:系统评价和荟萃分析。
Gerontology. 2022;68(10):1081-1090. doi: 10.1159/000521214. Epub 2022 Jan 13.
8
Influence of Drugs on Mild Cognitive Impairment in Parkinson's Disease: Evidence from the PACOS Study.药物对帕金森病轻度认知障碍的影响:来自 PACOS 研究的证据。
Curr Neuropharmacol. 2022;20(5):998-1003. doi: 10.2174/1570159X20666211223122800.

本文引用的文献

1
Association of Polypharmacy With Mild Cognitive Impairment and Cognitive Ability: A Nationwide Survey in Taiwan.多药治疗与轻度认知障碍和认知能力的关系:台湾的全国性调查。
J Clin Psychiatry. 2018 Sep 25;79(6):17m12043. doi: 10.4088/JCP.17m12043.
2
Association between polypharmacy and dementia - A systematic review and metaanalysis.多药治疗与痴呆的关联:系统评价和荟萃分析。
Aging Ment Health. 2019 Aug;23(8):932-941. doi: 10.1080/13607863.2018.1468411. Epub 2018 May 10.
3
Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study.新诊断帕金森病患者的脑葡萄糖代谢与认知:ICICLE-PD 研究。
J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):310-316. doi: 10.1136/jnnp-2016-313918. Epub 2016 Oct 6.
4
Effectiveness of medication review: a systematic review and meta-analysis of randomized controlled trials.药物评估的有效性:随机对照试验的系统评价与荟萃分析
BMC Fam Pract. 2017 Jan 17;18(1):5. doi: 10.1186/s12875-016-0577-x.
5
Association between polypharmacy and cognitive impairment in an elderly Japanese population residing in an urban community.在一个城市社区居住的日本老年人群体中,药物滥用与认知障碍之间的关联。
Geriatr Gerontol Int. 2017 Sep;17(9):1286-1293. doi: 10.1111/ggi.12862. Epub 2016 Sep 15.
6
MDS clinical diagnostic criteria for Parkinson's disease.帕金森病的MDS临床诊断标准。
Mov Disord. 2015 Oct;30(12):1591-601. doi: 10.1002/mds.26424.
7
Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review.社区居住老年人多重用药相关的健康结局:一项系统综述
J Am Geriatr Soc. 2014 Dec;62(12):2261-72. doi: 10.1111/jgs.13153.
8
Predictors of dementia in Parkinson disease: a prospective cohort study.帕金森病痴呆的预测因素:一项前瞻性队列研究。
Neurology. 2014 Sep 30;83(14):1253-60. doi: 10.1212/WNL.0000000000000842. Epub 2014 Aug 29.
9
Delirium in elderly people.老年人谵妄。
Lancet. 2014 Mar 8;383(9920):911-22. doi: 10.1016/S0140-6736(13)60688-1. Epub 2013 Aug 28.
10
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment.帕金森病患者的认知障碍:诊断、生物标志物和治疗。
Lancet Neurol. 2012 Aug;11(8):697-707. doi: 10.1016/S1474-4422(12)70152-7.